These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 28027596)

  • 1. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.
    van der Wouden CH; Cambon-Thomsen A; Cecchin E; Cheung KC; Dávila-Fajardo CL; Deneer VH; Dolžan V; Ingelman-Sundberg M; Jönsson S; Karlsson MO; Kriek M; Mitropoulou C; Patrinos GP; Pirmohamed M; Samwald M; Schaeffeler E; Schwab M; Steinberger D; Stingl J; Sunder-Plassmann G; Toffoli G; Turner RM; van Rhenen MH; Swen JJ; Guchelaar HJ;
    Clin Pharmacol Ther; 2017 Mar; 101(3):341-358. PubMed ID: 28027596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen.
    Manson LE; van der Wouden CH; Swen JJ; Guchelaar HJ
    Pharmacogenomics; 2017 Jul; 18(11):1041-1045. PubMed ID: 28685652
    [No Abstract]   [Full Text] [Related]  

  • 3. Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study.
    van der Wouden CH; Böhringer S; Cecchin E; Cheung KC; Dávila-Fajardo CL; Deneer VHM; Dolžan V; Ingelman-Sundberg M; Jönsson S; Karlsson MO; Kriek M; Mitropoulou C; Patrinos GP; Pirmohamed M; Rial-Sebbag E; Samwald M; Schwab M; Steinberger D; Stingl J; Sunder-Plassmann G; Toffoli G; Turner RM; van Rhenen MH; van Zwet E; Swen JJ; Guchelaar HJ;
    Pharmacogenet Genomics; 2020 Aug; 30(6):131-144. PubMed ID: 32317559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice.
    Cecchin E; Roncato R; Guchelaar HJ; Toffoli G;
    Curr Pharm Biotechnol; 2017; 18(3):204-209. PubMed ID: 28044932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of pharmacogenomics: Where are we now?
    Medwid S; Kim RB
    Br J Clin Pharmacol; 2024 Aug; 90(8):1763-1781. PubMed ID: 36366858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
    Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
    JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program.
    Dong OM; Bates J; Chanfreau-Coffinier C; Naglich M; Kelley MJ; Meyer LJ; Icardi M; Vassy JL; Sriram P; Heise CW; Rivas S; Ribeiro M; Jacobitz R; Rozelle S; Chapman JG; Voora D
    Pharmacogenomics; 2021 Feb; 22(3):137-144. PubMed ID: 33403869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
    Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
    Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-emptive pharmacogenomics implementation among polypharmacy patients 65 years old and older: a clinical pilot.
    Uber R; Hayduk VA; Pradhan A; Ward T; Flango A; Graham J; Wright EA
    Pharmacogenomics; 2023 Dec; 24(18):915-920. PubMed ID: 37965783
    [No Abstract]   [Full Text] [Related]  

  • 10. Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.
    Rosenman MB; Decker B; Levy KD; Holmes AM; Pratt VM; Eadon MT
    Value Health; 2017 Jan; 20(1):54-59. PubMed ID: 28212969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.
    Zhu Y; Swanson KM; Rojas RL; Wang Z; St Sauver JL; Visscher SL; Prokop LJ; Bielinski SJ; Wang L; Weinshilboum R; Borah BJ
    Genet Med; 2020 Mar; 22(3):475-486. PubMed ID: 31591509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenges of implementing pharmacogenomic testing in the clinic.
    Moyer AM; Caraballo PJ
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):567-577. PubMed ID: 28949250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A qualitative approach to assess the opinion of physicians about the challenges and prospects of pharmacogenomic testing implementation in clinical practice in Greece.
    Koufaki MI; Patrinos GP; Vasileiou KZ
    Hum Genomics; 2024 Jul; 18(1):82. PubMed ID: 39030587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx).
    Just KS; Steffens M; Swen JJ; Patrinos GP; Guchelaar HJ; Stingl JC
    Eur J Clin Pharmacol; 2017 Oct; 73(10):1247-1252. PubMed ID: 28669097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium.
    Pratt VM; Cavallari LH; Fulmer ML; Gaedigk A; Hachad H; Ji Y; Kalman LV; Ly RC; Moyer AM; Scott SA; Turner AJ; van Schaik RHN; Whirl-Carrillo M; Weck KE
    J Mol Diagn; 2024 Oct; 26(10):851-863. PubMed ID: 39032821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?
    Peruzzi E; Roncato R; De Mattia E; Bignucolo A; Swen JJ; Guchelaar HJ; Toffoli G; Cecchin E
    Br J Clin Pharmacol; 2023 Nov; ():. PubMed ID: 37926674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies.
    Nagy M; Attya M; Patrinos GP
    Pharmacogenomics; 2020 Nov; 21(17):1247-1264. PubMed ID: 33124490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implementation of preemptive pharmacogenomics in psychiatry.
    Skokou M; Karamperis K; Koufaki MI; Tsermpini EE; Pandi MT; Siamoglou S; Ferentinos P; Bartsakoulia M; Katsila T; Mitropoulou C; Patrinos GP;
    EBioMedicine; 2024 Mar; 101():105009. PubMed ID: 38364700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.